Atai Beckley N.V (ATAI)

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that the US Patent and Trademark Office has granted a new patent covering EMP-01, its oral R-MDMA formulation. The company said that the patent includes claims to the drug substance of EMP-01 and is expected to provide exclusivity through 2043.

9.55am: AI and semiconductors lead Nasdaq lower at open  Investors moved money out of US tech stocks on Thursday.  It was a mixed picture overall on Wall...

– Co-Founder Maximilian Martin Appointed CEO – – Co-Founder Christian Angermayer Appointed Executive Chairman – – Jim Murren to join Board of Directors – – Company Appoints Sid Banthiya Chief Financial Officer; Promotes Alex Lopez to Chief Brand Officer and Rick Adams to Chief Sporting Officer – – Names Chris Jones Chief Communications Officer – NEW YORK , Nov. 19, 2025 /PRNewswire/ -- Enhanced, the elite sports competition and performance products company committed to giving athletes and people alike the ability to optimize their health, performance and recovery, today announced that it has fortified its executive leadership team and its board of directors.  Enhanced Fortifies Executive Leadership Team & Board of Directors Co-Founder Maximilian Martin Appointed Chief Executive Officer Maximilian Martin, Co-Founder of Enhanced, has been appointed CEO and assumes all operational leadership duties for the company.

AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) reported continued clinical and operational progress during the third quarter of 2025, advancing multiple programs targeting treatment-resistant depression (TRD) and other mental health conditions. During the quarter, the company's lead candidate BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray, was granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for TRD.

Oklo (NYSE:OKLO) continued to invest in its pre-commercial nuclear technology during Q3, achieving several operational and regulatory milestones. Oklo...

Atai Beckley N.V. ( ATAI ) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression November 10, 2025 8:00 AM EST Company Participants Ashleigh Barreto Srinivas Rao - Co-Founder, CEO & Executive Director Kevin Craig - Chief Medical Officer Robert Conley - Chief Research & Development Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Ritu Baral - TD Cowen, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Harry Gillis - Joh.

AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) has unveiled positive topline results from the open-label extension (OLE) study of its Phase 2b clinical trial evaluating BPL-003 in patients with treatment-resistant depression (TRD). The company said that a 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 0.3 mg, 8 mg, or 12 mg dose produced additional rapid and clinically meaningful antidepressant effects that were sustained for up to eight weeks.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that its previously annoucned strategic combination with Beckley Psytech has been completed, forming a new clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders called AtaiBeckley. Atai Life Sciences shareholders approved the transaction and a corporate redomiciliation to Delaware at an Extraordinary General Meeting held on November 4, with approximately 98% of votes cast in favor.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced the completion of a $149.5 million public offering of approximately 27 million common shares, including the full exercise of underwriters' option to purchase an additional 3.6 million shares at $5.48 per share. The financing included participation from both new and existing investors, such as Janus Henderson Investors, Foresite Capital, Deep Track Capital, HBM Partners, Ferring Ventures, Columbia Threadneedle Investments, Ally Bridge Group, Woodline Partners LP, and ADAR1 Capital Management.

Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ATAI's main value driver is BPL-003. This candidate showed rapid and durable TRD benefits in its Phase 2b trials. BPL-003's 8 mg dose seemed to be ideal, which is why ATAI is going ahead with a Phase 3 with this dosing by Q2 2026. ATAI's broader pipeline includes VLS-01 DMT buccal film, EMP-01 R-MDMA for SAD, and other early-stage non-hallucinogenic 5-HT2A candidates.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has priced its registered underwritten offering of 23,725,000 company common shares at $5.48 per share, with expectations of raising about $130 million.  The clinical-stage biopharmaceutical company said it intends to use the net proceeds of the offering, together with existing cash, cash equivalents and short-term investments, to advance the clinical development of its product candidates and programs, as well as for working capital and general corporate purposes.

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adult patients with treatment-resistant depression (TRD). The FDA's Breakthrough Therapy designation is intended to accelerate the development of drugs for serious or life-threatening conditions where preliminary clinical evidence indicates the therapy may offer substantial improvement over existing treatments.

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of its common shares. atai expects to grant the underwriters a 30-day option to purchase additional common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.